Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.55 |
| ▸ | KCNA3 | P22001 | 10/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.47 |
| ▸ | CCR3 | P51677 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bezitramide SCHEMBL25733 | 1.00 | OPRM1 (0.55) | OPRM1KCNA3RAB9ANPSR1OPRL1 | |
| Bezitramide SCHEMBL28086670 | 0.83 | OPRM1 (0.52) | OPRM1KCNA3RAB9ANPSR1OPRL1 | |
| Bezitramide SCHEMBL466257 | 0.81 | OPRM1 (0.57) | OPRM1KCNA3OPRL1 | |
| Bezitramide SCHEMBL28086184 | 0.79 | SIGMAR1 (0.52) | OPRM1NPSR1 | |
| SCHEMBL2573257 | 0.71 | OPRM1 (1.00) | OPRM1KCNA3OPRL1 | |
| Hydrochloric Acid SCHEMBL11625263 | 0.71 | KCNA3 (0.97) | OPRM1KCNA3RAB9ANPSR1CCR3 | |
| SCHEMBL30659491 | 0.70 | KCNA3 (0.75) | OPRM1KCNA3RAB9ANPSR1CCR3 | |
| SCHEMBL904853 | 0.70 | CCR3 (0.55) | KCNA3CCR3 | |
| SCHEMBL3604592 | 0.69 | CACNA1G (0.58) | OPRM1OPRL1 | |
| SCHEMBL5858628 | 0.69 | DRD2 (0.61) | OPRM1KCNA3RAB9ANPSR1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3682872-B1 | LIQUISOFT CAPSULES | PATHEON SOFTGELS INC (US) | 2024-01-03 | — | — | EP | claimed |
| EP-3064199-B1 | ABUSE-DETERRENT TRANSDERMAL FORMULATIONS OF OPIATE AGONISTS AND AGONIST-ANTAGONISTS | BUZZZ PHARMACEUTICALS LTD (IE) | 2023-12-20 | — | — | EP | claimed |
| EP-3313407-B1 | TREATMENT AND MANAGEMENT OF AUGMENTATION IN RESTLESS LEGS SYNDROME | UNIV EAST CAROLINA (US) | 2023-07-19 | — | — | EP | claimed |
| EP-3385252-B1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARM INC (US) | 2022-09-21 | — | — | EP | claimed |
| EP-3291676-B1 | MITRAGYNINE ANALOGS AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-08-17 | — | — | EP | claimed |
| US-20250302768-A1 | NANOPARTICLE DOPED POLYETHYLENE GLYCOL BASED GELS AND MEDICAL DEVICES FOR DRUG DELIVERY | THE GENERAL HOSPITAL CORPORATION | 2025-10-02 | — | — | US | disclosed |
| CN-119212681-A | Method for preparing 3-D printed pharmaceutical products | 百时美施贵宝公司 | 2024-12-27 | — | — | CN | disclosed |
| WO-2023220717-A2 | NANOPARTICLE DOPED POLYETHYLENE GLYCOL BASED GELS AND MEDICAL DEVICES FOR DRUG DELIVERY | THE GENERAL HOSPITAL CORPORATION (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20230293695-A1 | Tamper Resistant Pharmaceutical Formulations | PURDUE PHARMA LP (US) | 2023-09-21 | — | — | US | disclosed |
| EP-1765303-B2 | ORAL TABLET SAFEGUARDED AGAINST ABUSE | GRUENENTHAL GMBH (DE) | 2022-11-23 | — | — | EP | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |